LE TRAN: Open Payments
NPI 1689122525 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,428 in 50 payments from 14 companies in 2025. Trend: 2023 $1,556 · 2024 $1,476 · 2025 $1,428
Food & beverage: $1,428
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 8 | $306 |
| Fresenius USA Marketing, Inc. | 19 | $235 |
| Ardelyx, Inc. | 3 | $168 |
| Amgen Inc. | 3 | $155 |
| AKEBIA THERAPEUTICS INC | 1 | $125 |
| Calliditas Therapeutics US Inc. | 3 | $115 |
| SHIELD THERAPEUTICS INC | 2 | $89 |
| GlaxoSmithKline, LLC. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Pharmacosmos Therapeutics Inc. | 2 | $43 |
Products named: VELPHORO, KRYSTEXXA, Filspari, Vafseo, XPHOZAH 30 MG, TARPEYO, ACCRUFER, BENLYSTA.
Industry payments across OK — which companies pay providers there.
